The U.S. Food and Drug Administration approved Rhythm Pharmaceuticals’ setmelanotide (IMCIVREE) for the treatment of acquired hypothalamic obesity (HO) on March 19 2026. The approval extends the drug’s label to adults and children four years of age and older, adding an estimated 10,000 U.S. patients to the company’s addressable market.
The decision was based on the Phase 3 TRANSCEND trial, which enrolled 142 patients and demonstrated a 18.4% placebo‑adjusted reduction in body‑mass index. The trial also reported a mean BMI decrease of 15.8% for patients receiving setmelanotide versus a 2.6% increase in the placebo group at 52 weeks, confirming the drug’s efficacy in this rare condition.
Rhythm’s leadership views the approval as a strategic milestone that could unlock a market opportunity of more than $1 billion, with some analysts projecting peak global sales exceeding $2 billion by 2030. The approval establishes the company as the sole FDA‑approved therapy for acquired HO, giving it a first‑to‑market advantage in a previously untreatable orphan disease.
Financially, Rhythm reported Q4 2025 revenue of $57.3 million, up 12% sequentially and 37% year‑over‑year, and full‑year 2025 revenue of $194.8 million, a 50% increase from $130.1 million in 2024. The company posted a net loss of $201.9 million for 2025 and is guiding 2026 operating expenses between $385 million and $415 million, reflecting investments in next‑generation MC4R agonists, the HO commercial launch, and Japanese operations.
David Meeker, M.D., Chairman, CEO, and President of Rhythm, said, “IMCIVREE is now the first and only FDA‑approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options.” The company’s strategy to double its revenue base now includes the HO indication, reinforcing its position in the rare‑disease market.
Investors reacted positively to the announcement, citing the approval’s potential to open a multi‑billion‑dollar market and the company’s strong track record of expanding its product portfolio in orphan indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.